Impax Asset Management Group plc Has $5.93 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Impax Asset Management Group plc boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,643 shares of the biopharmaceutical company’s stock after acquiring an additional 248 shares during the quarter. Impax Asset Management Group plc’s holdings in Regeneron Pharmaceuticals were worth $5,932,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $26,000. Sachetta LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Finally, Family Firm Inc. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.1 %

REGN opened at $829.43 on Wednesday. The firm’s fifty day moving average is $1,043.57 and its two-hundred day moving average is $1,039.92. The firm has a market cap of $91.44 billion, a PE ratio of 20.53, a price-to-earnings-growth ratio of 2.90 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a twelve month low of $783.57 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 7.48% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Leerink Partners restated a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Finally, Royal Bank of Canada reduced their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,097.25.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.